Cerity Partners LLC Boosts Stock Holdings in Boston Scientific Corporation $BSX

Cerity Partners LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,301,504 shares of the medical equipment provider’s stock after acquiring an additional 10,625 shares during the quarter. Cerity Partners LLC owned approximately 0.09% of Boston Scientific worth $139,794,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. 1248 Management LLC bought a new stake in Boston Scientific in the 1st quarter worth about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the 1st quarter worth approximately $27,000. Sound Income Strategies LLC grew its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. Kilter Group LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $30,000. Finally, Princeton Global Asset Management LLC bought a new stake in Boston Scientific during the second quarter worth $32,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

BSX opened at $97.46 on Friday. The firm has a 50-day moving average price of $99.27 and a 200-day moving average price of $102.04. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $144.48 billion, a price-to-earnings ratio of 52.12, a PEG ratio of 1.96 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the firm earned $0.63 EPS. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

BSX has been the subject of a number of recent analyst reports. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. UBS Group lifted their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Needham & Company LLC reissued a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $123.77.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 143,095 shares of company stock worth $14,228,950. 0.50% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.